Smad7: licensed to kill beta-catenin
- PMID: 16950118
- DOI: 10.1016/j.devcel.2006.08.008
Smad7: licensed to kill beta-catenin
Abstract
Elevated levels of inhibitory Smad7 are detected in several pathologic skin conditions; however the functional consequences of this expression have been unclear. A recent study shows that Smad7 overexpression in transgenic mouse epidermis at levels comparable to those seen in pathologic states is insufficient to block TGFbeta or BMP signaling, but instead produces striking phenotypes due to degradation of beta-catenin through a novel mechanism involving Smad7 and Smurf2.
Comment on
-
Smad7-induced beta-catenin degradation alters epidermal appendage development.Dev Cell. 2006 Sep;11(3):301-12. doi: 10.1016/j.devcel.2006.06.014. Dev Cell. 2006. PMID: 16950122
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical